Research infrastructure, oral peptide rights and sustained funding

1. CSL links its research workflow to AWS AI services¹

CSL announced a collaboration with Amazon Web Services to bring AI services into its biopharmaceutical research and development workflow. The company describes connecting laboratory work with computational analysis, including target identification, clinical protocols, data interpretation and regulatory preparation, using AWS services such as Amazon Bedrock. The development matters as an organisational commitment to shared research infrastructure across those tasks. CSL says the work will remain governed by its scientific standards. The announcement outlines intended capabilities and implementation ambitions; it provides no controlled evidence that the collaboration has improved drug-development speed, quality or clinical success.¹

2. Estonia and Owkin plan a controlled biological AI evaluation²

Owkin and Estonia’s Metrosert announced plans to evaluate Owkin’s K Pro biological AI platform within secure national infrastructure. The initial work concerns selected health-data cohorts and access for approved researchers, with oncology among the proposed applications linking clinical, molecular, imaging and treatment-outcome information. For research teams, the consequential development is a proposed route to testing biological AI against governed local data. It is not an announcement that Estonia’s entire health database has been opened to the company. The release describes an evaluation and collaboration; clinical utility, research productivity and the eventual scale of deployment remain to be demonstrated.²

3. Novo licenses Hengrui’s oral dual-agonist programme³

Novo Nordisk announced an agreement to license Hengrui’s HRS-1596, a GLP-1/GIP dual receptor agonist intended for potential once-weekly oral dosing. The agreement includes a $300 million upfront payment and could reach $2.6 billion if development, regulatory and commercial milestones are achieved, with additional sales royalties. Novo would obtain development, manufacturing and commercial rights outside mainland China, Hong Kong, Macao and Taiwan. The phase 1-ready programme adds a substantial development commitment to oral peptide pharmacology. Once-weekly use and patient benefit remain prospective, and the agreement still requires regulatory clearance and other closing conditions.³

4. A £50 million centre backs restorative immunology research⁴

UK Research and Innovation announced £50 million of Medical Research Council support for a Centre of Research Excellence in Restorative Immunology. The programme brings Birmingham and Kyoto together with six other UK universities over a 14-year horizon to investigate how immune dysfunction and tissue damage might be reversed. Its plans include tissue mapping and models for testing more precise therapeutic approaches. The scale and duration make this a consequential commitment to the foundations of inflammatory-disease pharmacology. The centre’s ambition to pursue cures describes its research objective; the funding announcement does not establish that any new treatment is effective.⁴

5. AN2 secures extended support for its tuberculosis programme⁵

AN2 Therapeutics announced extended Gates Foundation funding for its tuberculosis research collaboration with GSK. The programme develops boron-containing inhibitors of leucyl-tRNA synthetase, an antibacterial target involved in protein synthesis. Continued support is a concrete development commitment for a neglected-disease drug-discovery programme, rather than a new paper or an efficacy readout. The company’s announcement does not disclose the additional funding amount or its duration, so the extension cannot be quantified from this release. Its therapeutic promise remains dependent on the subsequent discovery and development work; the announcement itself does not demonstrate successful treatment of tuberculosis.⁵